Evidence map›Paper›PMID 27643872›Full record

Trial reportBone marrow transplantation2017

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, R Bouadballah, J Radford, M Bargetzi, V Ribrag and 8 more

Abstract readClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

E Van Den NesteCliniques Universitaires UCL Saint-Luc, Brussels, Belgium.
N SchmitzAsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.
N MounierCHU de l'Archet, route de St Antoine-Ginestiere, Nice, France.
D GillPrincess Alexandra Hospital, Woodville, South Australia, Australia.
D LinchUniversity College London, Cancer Institute, London, UK.
M TrnenyCharles University and General Hospital, Praha, Czech Republic.
R BouadballahInstitut Paoli Calmette Département d'Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France.
J RadfordUniversity of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
M BargetziHämatologie, Kantonsspital Aarau, Aarau, Switzerland.
V RibragInstitut Gustave Roussy, Villejuif, France.
U DührsenUniversitätsklinikum Essen, KlinikfürHämatologie-Hufelandstraße, Essen, Germany.
D MaSt Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
J BriereHopital Saint Louis Paris, Paris, France.
C ThieblemontHopital Saint Louis Paris, Paris, France.
E BachyHospices Civils de Lyon, Université de Lyon, Pierre Benite, France.
C H MoskowitzMemorial Sloan Kettering Cancer Center, New York, NY, USA.
B GlassAsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.
C GisselbrechtHopital Saint Louis Paris, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed <6 months (5.7 months) compared with those relapsing ⩾12 months after ASCT (12.6 months, P=0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P<0.0001), 10.0 (P=0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and >2: 5.3 months (P=0.0007). In multivariate analysis, tIPI >2, achievement of response and remission lasting <6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.

Indexed as

Stem Cell TransplantationAdolescentAdultAgedAutograftsDisease-Free SurvivalFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedRecurrenceSurvival Rate

Identifiers

PMID27643872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.